Today: 16 October 2025
Subscribe
Innoviz Stock Skyrockets on LiDAR Boom and Big Autonomous Driving Deals
 ·  ·  ·  · 

Innoviz Stock Skyrockets on LiDAR Boom and Big Autonomous Driving Deals

by
15 October 2025
  • Price surge: INVZ traded around $2.38 as of mid-Oct 2025 [1], up ~29% in the last month and 219% year-over-year [2]. (One-day gain on Oct.14 was +9.2%.)
  • Market cap & targets: Market cap is roughly $438M [3]. Analysts’ 12‑month consensus price target is about $3.27 (≈+37% upside) [4]; the consensus rating averages between Hold and Strong Buy.
  • Financial results & guidance: Q2 2025 revenues were $9.7M (vs $6.7M YoY) [5], with record H1 revenues exceeding all of 2024 [6]. Innoviz reiterated its FY2025 sales guidance of $50–60M and raised its 2025 non-recurring engineering (NRE) bookings target to $30–60M [7]. (Cash burn in Q2 was reduced to single digits [8].)
  • Major contracts: Innoviz has landed multiple high‑profile design wins. A “Top‑5” passenger car OEM signed a development deal for InnovizTwo LiDAR on a Level-3 vehicle (SOP 2027) [9]. A leading Class-8 truck maker selected InnovizTwo for future Level-4 autonomous trucks [10]. (Volkswagen’s MOIA already uses Innoviz for its ID.Buzz L4 shuttle [11].)
  • Strategic partnerships: The company is expanding beyond vehicles. It teamed with Cron AI and D2 Traffic to deploy LiDAR at smart intersections [12], and with Cogniteam (Italy) to offer a 400m-range InnovizSMART security/AI solution [13]. Other collaborations include Sparsh CCTV for Indian transit and NVIDIA integration for InnovizSMART.
  • Product/certification updates: In June 2025 Innoviz launched InnovizSMART, a long-range LiDAR (400m) built on its auto-grade tech for industrial and smart‑city applications [14]. On Sept. 30 it earned ISO/IEC 17025:2017 accreditation for its hardware testing labs [15], enabling faster in‑house qualification of LiDAR components.
  • Industry context: The global LiDAR market is booming. About 1.6 million LiDAR units shipped in 2024 (over double 2023 levels) [16], and forecasts project ~25% annual growth, reaching ~$10B by 2033 [17]. Chinese EV makers dominate the space: in 2024 Chinese firms accounted for ≈93% of automotive LiDAR unit volume (Hesai ~33% share) [18]. (By contrast, Western OEMs mostly reserve LiDAR for premium models and robo-taxis [19].)

Innoviz’s recent stock surge reflects these positive fundamentals. CEO Omer Keilaf emphasized in the Q2 report that “we generated more revenues than in all of 2024” in H1 and drove cash burn into low single digits [20]. He noted Innoviz has begun shipping units from its new Fabrinet production line and is advancing its L3 and L4 programs. Keilaf also highlighted the InnovizSMART product, calling it “built on the same technological foundation as [our] automotive solutions” for smart infrastructure [21]. These comments underscore that Innoviz is not only growing sales but also diversifying into security, traffic and robotics markets.

Analysts agree growth is accelerating. A Goldman Sachs analyst (Mark Delaney) upgraded INVZ to Buy in late Sept. 2025, lifting his price target to $2.50. Delaney cited an influx of design-win opportunities and noted Innoviz trades at a discount to peers [22]. He argued that as “autonomous driving technology becomes increasingly important for automakers, new advanced driver-assistance and autonomous vehicle program awards should accelerate” [23]. Delaney pointed to Innoviz’s programs with a top-five automaker and a Class‑8 truck OEM as evidence that the company could soon secure series-production contracts [24]. In his models, Innoviz revenue could reach about $150M by 2028 under current plans, with upside toward $250M if AV adoption rises faster [25]. (He projects 2028 EBITDA breakeven in his base case.)

Other experts highlight the broader market tailwinds. An industry analyst noted that ≈40 auto OEMs were using LiDAR by 2024 (up from 8 in 2021) – most of them in China [26]. With camera and radar technologies advancing, Tesla famously eschews LiDAR; but others like Ford have openly endorsed LiDAR as “critical for safety” in self-driving [27]. Innoviz’s use of 905-nm laser technology (safer for eyes/cameras than 1550-nm beams) has also drawn interest amid recent headlines about Luminar’s 1550-nm units damaging camera sensors [28].

On valuation, Innoviz still trades at a high ratio – around 12.7× price-to-sales [29], reflecting expectations of rapid growth. The company’s cash reserves (~$79M at Q2-end [30]) and milestone bookings provide a buffer while it executes on its roadmap. The upcoming Q3 results (due Nov. 12, 2025 [31]) will be closely watched for progress on these fronts. In summary, while INVZ remains a speculative small‑cap, its recent momentum is backed by concrete wins and a booming LiDAR market. As one analyst put it, Innoviz’s blend of “strong customer engagement and units now shipping from our high-volume manufacturing line” suggests it’s on track to capitalize on the surge in autonomous-vehicle technology [32] [33].

Sources: Innoviz press releases and filings [34] [35]; financial news reports and analyses [36] [37] [38] [39]; stock data (Yahoo/Investing) [40] [41].

Innoviz discusses LiDAR for Autonomous Driving with MIT Students
Watch this video on YouTube.

References

1. www.stocktitan.net, 2. simplywall.st, 3. www.stocktitan.net, 4. stockanalysis.com, 5. ir.innoviz.tech, 6. ir.innoviz.tech, 7. ir.innoviz.tech, 8. ir.innoviz.tech, 9. ir.innoviz.tech, 10. ir.innoviz.tech, 11. www.prnewswire.com, 12. ir.innoviz.tech, 13. www.stocktitan.net, 14. ts2.tech, 15. ir.innoviz.tech, 16. ts2.tech, 17. www.marketreportanalytics.com, 18. ts2.tech, 19. ts2.tech, 20. ir.innoviz.tech, 21. ts2.tech, 22. www.benzinga.com, 23. www.benzinga.com, 24. www.benzinga.com, 25. www.benzinga.com, 26. www.wevolver.com, 27. ts2.tech, 28. www.designnews.com, 29. simplywall.st, 30. ir.innoviz.tech, 31. stockanalysis.com, 32. ir.innoviz.tech, 33. www.benzinga.com, 34. ir.innoviz.tech, 35. ir.innoviz.tech, 36. simplywall.st, 37. www.benzinga.com, 38. ts2.tech, 39. www.marketreportanalytics.com, 40. www.stocktitan.net, 41. stockanalysis.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. Redwire (RDW) Shares Plummet on Shake-Up – Is a Takeoff Next?
  2. HOVR Stock Rockets as Horizon Aircraft Lands Pratt & Whitney Engine Partnership
  3. Rocket Lab (RKLB) Stock Blasts Off: Japan Launch Deals and Analyst Upgrades Fuel 700% Rally
  4. Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Related Articles

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough
Previous Story

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

FuelCell Energy Stock Skyrockets on AI Data Center Boom – 97% Revenue Surge Ignites Green Energy Hype
Next Story

FuelCell Energy Stock Skyrockets on AI Data Center Boom – 97% Revenue Surge Ignites Green Energy Hype

Stock Market Today

  • Bristol-Myers Squibb (BMY) tops Partha Mohanram's P/B Growth model at 88%
    October 15, 2025, 6:12 PM EDT. Bristol-Myers Squibb (BMY) posts a standout reading under Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and topping 22 guru strategies. The growth model seeks low book-to-market stocks with sustained future growth, placing BMY in the large-cap Biotechnology & Drugs space with a growth tilt. An 88% rating signals notable interest (with >90% signaling stronger conviction). The analysis shows mostly PASS across tests-Book/Market, ROA, CFO to Assets, CFO/ROA, ROA variance, Sales variance, Advertising to Assets, Capex to Assets-while R&D to Assets failed. Validea frames this as a meaningful signal from the growth framework and from Mohanram's research.
  • BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals High Interest
    October 15, 2025, 6:10 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth model, giving an 88% score. This large-cap growth stock in Biotechnology & Drugs benefits from a low book-to-market profile and fundamentals that support sustained growth. In Validea's framework, a score above 80% signals interest, with above 90% indicating strong interest-BMY sits at 88%. The model reports PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with RESEARCH AND DEVELOPMENT TO ASSETS and ADVERTISING TO ASSETS highlighted. Overall, the Mohanram-based view portrays BMY as a growth-oriented, fundamentally solid pick within its sector, though investors should consider the broader biotech landscape.
  • BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals 88% Rating
    October 15, 2025, 6:08 PM EDT. Validea's guru-based view on Bristol-Myers Squibb (BMY) shows strong alignment with Partha Mohanram's P/B Growth Investor model. The strategy seeks low book-to-market stocks with sustained growth, and BMY earns an 88% rating, suggesting meaningful interest (scores above 80% indicate some interest; above 90% indicate strong interest). BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The table of tests indicates several criteria are PASS (e.g., Book/Market, Return on Assets, Cash Flow from Operations to Assets) with other metrics also favorable. Overall, the rating implies a constructive signal from this growth-based framework, though investors should consider broader fundamentals and market conditions alongside this model's outputs.
  • BMY Factor-Based Stock Analysis: Partha Mohanram Growth Signal Dominates Validea
    October 15, 2025, 6:06 PM EDT. Validea's guru fundamental report highlights Bristol-Myers Squibb Co (BMY) as a top pick under the P/B Growth Investor model from Partha Mohanram. Among 22 guru strategies, BMY earns the highest reads from this growth approach, reflecting a preference for low book-to-market stocks with signs of sustained future growth. The stock weighs in at 88% under this model, with a typical threshold of 80% to show interest and 90% for strong interest. The accompanying test table shows many positives-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS-while RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAILED. BMY is a large-cap player in the Biotechnology & Drugs sector, reinforcing its growth tilt despite mixed indicators.
  • BMY Factor-Based Stock Analysis: Mohanram Growth Model Highlights
    October 15, 2025, 6:04 PM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks under Validea's Partha Mohanram P/B Growth Investor model, signaling potential near-term strength in a large-cap Biotechnology & Drugs role. The growth-oriented screen flags BMY with an 88% rating, suggesting strong fundamentals and favorable valuation. Core tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS pass, while factors like ADVERTISING TO ASSETS and CAPITAL EXPENDITURES TO ASSETS are also favorable. The model aims to identify low book-to-market stocks with sustained growth, and BMY appears consistent with that thesis. As always, consider other factors and risk in any decision.
Go toTop